GO
Loading...

Schering-Plough Gets EU Approval for Hepatitis C Treatment

AP
Monday, 25 Jun 2007 | 8:54 AM ET

Drug maker Schering-Plough said Monday it received expanded European approval for a combination therapy of Pegintron and Rebetol to treat hepatitis C patients who are also infected with HIV.

The combination therapy was originally approved in Europe in March 2001 for the treatment of hepatitis C alone. Both drugs are made by Schering-Plough .

The latest approval was based on two clinical studies showing that hepatitis C patients, with HIV, who were given Pegintron and Rebetol had significantly lower amounts of the hepatitis C virus six months after treatment compared with those patients given conventional interferon alfa-2b and ribavirin.

The company said about 40 percent of the 2.5 million people living in Europe with HIV were also infected with chronic hepatitis C.

Featured

Contact U.S. News

  • CNBC NEWSLETTERS

    Get the best of CNBC in your inbox

    › Learn More

Don't Miss

U.S. Video

  • CNBC's David Faber and Carl Icahn, chairman, Icahn Enterprises, discuss corporate boards, a dysfunctional system, his impact as an activist investor and why what he does is important, as well as the use of poison pills to fend off activists. He also finds himself in the unusual position of defending Bill Ackman's recent efforts to partner with Valeant and acquire Allergan.

  • Discussing new technology in the Permian, growing market in North America, and higher earnings, with Dave Lesar, Halliburton chairman, president and CEO.

  • Paul Raines, GameStop CEO, discusses how its leadership in digital sales, market share, and ability to drive loyalty with rewards propels consumers to stay with the gaming store.